Symposium 3
Symposium 6
Symposium 9
Breakfast Symposium 3
Symposium 12
Plenary Lecture 1
Special Lecture 1
Luncheon Symposium 3
Symposium 15
Keynote Lecture 1
Symposium 18
Breakfast Symposium 7
Symposium 20
Plenary Lecture 2
Keynote Lecture 2
Luncheon Symposium 7
Special Lecture 2
Symposium 22
Symposium 24
09. 11(Thu)
09. 11(Thu) 13:00~14:30 Room 3
TBD
09. 11(Thu) 14:40~16:10 Room 3
CVD Risk Prediction in Special Population
09. 11(Thu) 16:20~17:50 Room 3
How Low is Low Enough for LDL-C in Diabetes?
09. 12(Fri)
09. 12(Fri) 07:30~08:30 Room 3
09. 12(Fri) 08:30~10:00 Room 3
TBD
09. 12(Fri) 10:20~11:00 Room 3
09. 12(Fri) 11:05~11:45 Room 3
09. 12(Fri) 12:00~13:00 Room 3
09. 12(Fri) 13:00~14:30 Room 3
Nontraditional Risk Factors for ASCVD
- Environmental pollution as a nontraditional risk factor for atherosclerotic cardiovascular disease: mechanisms and impacts 13:00~13:20
- Health inequity and its role as a nontraditional risk factor in the prevalence and severity of ASCVD 13:20~13:40
- Sleep disorders: an overlooked nontraditional risk factor in atherosclerotic cardiovascular disease development 13:40~14:00
- Panel Discussion 14:00~14:30
09. 12(Fri) 15:50~16:30 Room 3
09. 12(Fri) 16:45~18:15 Room 3
Sex and Gender Differences in Cardiometabolic Health: From Biology to Treatment
09. 13(Sat)
09. 13(Sat) 07:50~08:50 Room 3
09. 13(Sat) 08:50~10:10 Room 3
Optimized Management of Cardiometabolic Syndrome in the Elderly: Focus on Multimorbidity and Frailty
- Strategies for managing hyperlipidemia in fragile elderly patients 08:50~09:10
- Optimizing glucose control in fragile elderly patients with cardiometabolic syndrome 09:10~09:30
- How to deal with multimorbidity and frailty for the prevention of cardiovascular disease 09:30~09:50
- Panel Discussion 09:50~10:20
09. 13(Sat) 10:40~11:20 Room 3
09. 13(Sat) 11:25~12:05 Room 3
09. 13(Sat) 13:30~14:40 Room 3
09. 13(Sat) 14:50~16:20 Room 3
Atherosclerosis Beyond Traditional Risks: Emerging Clinical Challenges in Comorbid Conditions
- Atherosclerosis and lipid management in cancer survivors: balancing cardiovascular and oncologic risks 14:50~15:10
- Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk equivalent 15:10~15:30
- Atherosclerosis in chronic inflammatory diseases: focus on rheumatoid arthritis and systemic autoimmunity 15:30~15:50
- Panel Discussion 15:50~16:20
09. 13(Sat) 16:20~17:50 Room 3
Emerging Therapeutics Targeting Myocardial-vascular Interaction in Atherosclerotic Disease
- IKKε-deficient macrophages impede cardiac repair after myocardial infarction by enhancing the macrophage-myofibroblast transition 16:20~16:40
- Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis 16:40~17:00
- Roles of MCU in human platelets on platelet aggregation 17:00~17:20
- Panel Discussion 17:20~17:50
